MedTrace Logo

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

NCT06014762 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-05-07

No results posted yet for this study

Summary

Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

Conditions

  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • High-grade B-cell Lymphoma
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • Transformed Follicular Lymphoma (tFL)
  • Follicular Lymphoma Grade 3B
  • DLBCL
  • DLBCL - Diffuse Large B Cell Lymphoma
  • DLBCL Arising From Follicular Lymphoma
  • DLBCL, Diffused Large B Cell Lymphoma
  • DLBCL NOS

Interventions

BIOLOGICAL

P-CD19CD20-ALLO1

Single weight-based IV administration

DRUG

Rimiducid

Single weight-based IV administration

Sponsors & Collaborators

  • Roche-Genentech

    collaborator INDUSTRY

  • Poseida Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Simon Heidegger, MD · Lead Medical Director, Oncology, Genentech Research Early Development

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-16
Primary Completion
2029-03-31
Completion
2041-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06014762 on ClinicalTrials.gov